sorafenib has been researched along with Metabolic Syndrome in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Galle, PR; Huber, Y; Koch, S; Labenz, C; Marquardt, JU; Prenosil, V; Schattenberg, JM; Weinmann, A; Wörns, MA | 1 |
| Barbare, JC; Belghiti, J; Castaing, D; Chirica, M; Farges, O; Paradis, V; Soubrane, O; Vullierme, MP | 1 |
1 review(s) available for sorafenib and Metabolic Syndrome
| Article | Year |
|---|---|
Hepatocellular carcinoma--what's new?
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Hepatectomy; Humans; Liver Neoplasms; Liver Transplantation; Metabolic Syndrome; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Risk Factors; Sorafenib; Treatment Outcome | 2010 |
1 other study(ies) available for sorafenib and Metabolic Syndrome
| Article | Year |
|---|---|
Impact of Individual Components of the Metabolic Syndrome on the Outcome of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Female; Humans; Liver Neoplasms; Male; Metabolic Syndrome; Middle Aged; Multivariate Analysis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Retrospective Studies; Sorafenib; Survival Analysis; Treatment Outcome; Young Adult | 2018 |